* * Must be enrolled in our medical weight loss program to qualify for GLP-1 weight loss medication Our patients lose an average of 13% bodyweight in just 3 months with our medical weight loss programmore than double what patients see with GLP-1 medications alone.* Request more info below and a patient care coordinator will reach out to you to help set up your first consultation
32 The SOUL trial evaluated oral semaglutide in patients with T2D who had established atherosclerotic cardiovascular disease, chronic kidney disease (CKD), or both
Dosing Strategy and Individualized Titration At Taylor Bariatric Institute, topiramate is titrated gradually to minimize side effects and identify the most effective dose for each patient
Statistical heterogeneity between studies was quantified using Cochrans Q test
Better yet, the participants of our medical weight loss program enjoy ongoing physician supervision and support from our care team
Appetite changes, hormonal shifts, and new nutrient needs are all part of the process